Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000232 · ClinicalTrials.gov registry record · Phase 2
Alternate Day Buprenorphine Administration, Phase IX - 14
A Phase 2 study of Opioid-Related Disorders, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00000232: Completed Phase 2 study of Opioid-Related Disorders, sponsored by University of Vermont.
NCT00000232 is a Phase 2 study of Opioid-Related Disorders that has completed, run by University of Vermont. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000232, a Phase 2 study of Opioid-Related Disorders, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
Conditions Studied
Interventions
- DRUG Buprenorphine
Study Locations (1)
Vermont
- Treatment Research Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-03 |
| Phase | Phase 2 |
What the finished NCT00000232 record still lists
NCT00000232 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000232 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT00000232 about?
NCT00000232 is a clinical study titled "Alternate Day Buprenorphine Administration, Phase IX - 14". The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
What is the current status of trial NCT00000232?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-03.
What conditions does trial NCT00000232 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT00000232?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000232?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000232 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Alternate-Day Buprenorphine Administration. Phase VII - 8
COMPLETED · Phase 2
-
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia